Skip to content

Cash ratio at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
0.2×0.0×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
0.6×-0.5×
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
0.9×0.0×
iRadimed logo
iRadimedIRMD
4.7×-1.3×
Ginkgo Bioworks logo
Ginkgo BioworksDNA
2.4×-0.7×
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
0.8×0.0×

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Calculated from Rapid Micro Biosystems’s reported figures.

Based on the most recent quarter.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's cash ratio?
Rapid Micro Biosystems (RPID) reported cash ratio of 0.7× in Q1 2026.
How has Rapid Micro Biosystems's cash ratio changed year-over-year?
Rapid Micro Biosystems's cash ratio decreased by 42.6% year-over-year, from 1.3× to 0.7×.
What is the long-term trend for Rapid Micro Biosystems's cash ratio?
Over 5 years (2020 to 2025), Rapid Micro Biosystems's cash ratio has grown at a -10.8% compound annual growth rate (CAGR), from 1.9× to 1.1×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.